Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.67 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2864120 | 0.90 | DNM1 (0.71) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| SCHEMBL29496398 | 0.89 | DNM1 (0.80) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| SCHEMBL9462860 | 0.88 | DNM1 (0.60) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| SCHEMBL3840485 | 0.87 | DNM1 (0.67) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL23198627 | 0.86 | DNM1 (0.75) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| Bromide SCHEMBL126636 | 0.86 | DNM1 (0.81) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL124627 | 0.86 | DNM1 (0.75) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| Bromide SCHEMBL302420 | 0.86 | DNM1 (0.81) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| Iodide SCHEMBL187956 | 0.86 | DNM1 (0.75) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| SCHEMBL9303471 | 0.86 | DNM1 (0.75) | DNM1BDKRB2TSHRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842843-B2 | Mixture containing 1,3-butadiene and process for producing the same | KURARAY CO., LTD. (JP) | 2010-11-30 | — | — | US | disclosed |
| US-7728180-B2 | Method for producing ethers | KURARAY CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080262272-A1 | Method For Producing Ethers | KURARAY CO., LTD. (JP) | 2008-10-23 | — | — | US | disclosed |
| EP-1795578-A2 | Mixture containing 1, 3-Butadiene and process for producing the same | Kuraray Co., Ltd. (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-20070123738-A1 | MIXTURE CONTAINING 1,3-BUTADIENE AND PROCESS FOR PRODUCING THE SAME | KURARAY CO., LTD (JP) | 2007-05-31 | — | — | US | disclosed |
| EP-1760061-A1 | METHOD FOR PRODUCING ETHERS | KURARAY CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-4399272-A | COPOLYMERIZING FORMALDEHYDE AND AN ALKYLENE OXIDE OR CYCLIC FORMAL USING A LEWIS ACID AND ANIONIC CATALYST | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1983-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123738-A1 | MIXTURE CONTAINING 1,3-BUTADIENE AND PROCESS FOR PRODUCING THE SAME | TELO2, MSMO1, HBG1 | DNM1 1802/4885BDKRB2 2109/4885TSHR 4283/4885 |
| US-20080262272-A1 | Method For Producing Ethers | TELO2, PDS5A, TERT | DNM1 1280/4885BDKRB2 3298/4885TSHR 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.